openPR Logo
Press release

Datamonitor Healthcare Osteoporosis KOL Interviews

08-08-2017 08:34 AM CET | Health & Medicine

Press release from: ReportsWorldwide

ReportsWorldwide has announced the addition of a new report title Datamonitor Healthcare Osteoporosis KOL Interviews to its growing collection of premium market research reports.

For a Detailed description and table of contents of this report please click here: https://www.reportsworldwide.com/report/datamonitor-healthcare-osteoporosis-kol-interviews

February 03, 2017
Datamonitor Healthcare interviewed an endocrinologist based in the US and a rheumatologist based in the UK to gauge their views on current treatment options, late stage clinical candidates, treatment challenges and unmet needs in osteoporosis. The drugs discussed include abaloparatide (RDUS), Atelvia (AGN), Evenity (AMGN), Evista (LLY), Forteo (LLY), Fosamax (MRK), Prolia (AMGN) and Reclast (NVS). The two interviews were combined into a single report.

To Get Sample Copy of Report please visit @ https://www.reportsworldwide.com/enquiry?report_id=41342

About ReportsWorldwide.com

ReportsWorldwide.com is a leading provider of global market intelligence reports and services. With research reports from top publishers, consulting and advisory firms, ReportsWorldwide.com offers instant online access to a growing database of expert insights on global industries, companies, products, geographies and trends.

Press Contact:
Abigail Crasto
Senior Vice President
101, Arch Street
Boston, MA 02110
US
Phone +1 (617) 398-4994
Fax +1 (617) 398-4995
abigail@reportsworldwide.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Datamonitor Healthcare Osteoporosis KOL Interviews here

News-ID: 658628 • Views: 270

More Releases from ReportsWorldwide

World Deep Brain Stimulation Market Top Segments, Key Players Revenue, Growth Ra …
The World Deep Brain Stimulation Market is estimated to represent a global market of USD 751.8 million by 2017 with growth rate of 18.2%. Deep brain stimulation (DBS) procedure is primarily used for the treatment of neuropsychiatric disorders such as mood disorder, dementia, anxiety and others. The procedure involve the use of neurotransmitter (brain pacemaker) that enables to transmit electric impulses to the specific target of brain cells. Increasing incidence
New report explores the Gene Editing Market : Ushering The Next Breakthrough in …
Boston, MA ReportsWorldwide has announced the addition of a new report title Gene Editing The Next Breakthrough in Regenerative Medicine to its growing collection of premium market research reports. Genome editing is a type of genetic engineering in which DNA is replaced, inserted or deleted in a living organism's ggenome using engineered molecular scissors. Believed to be one of the great biotechnology breakthroughs, gene editing is a powerful tool in pharmaceutical research that
Global In-Building Wireless BTSController-based Small Cells Market Analysis and …
Boston, MA ReportsWorldwide has announced the addition of a new report title Global In-Building Wireless BTSController-based Small Cells Market Analysis and Forecast, 2017-2021 to its growing collection of premium market research reports. This report covers the leading in-building wireless enterprise BTS/controller-based small cells network equipment manufacturers: • CommScope/Airvana • Comba Telecom • Ericsson • Huawei Technologies • Nokia • SpiderCloud • ZTE Corporation This report covers the global market share for 2016 shipments as well as a forecast for 2017-2021. To view a detailed description and Table of
UDAY’s Impact and Compatibility State wise indexing of Integrated Power Supply …
Boston, MA ReportsWorldwide has announced the addition of a new report title UDAY’s Impact and Compatibility State wise indexing of Integrated Power Supply Chain in India – 2017 to its growing collection of premium market research reports. UDAY scheme was touted as the next paladin to bail out the struggling Discoms, in order to turn them green in a time horizon of 3-4 years from 2015/16. Though was optional for the

All 5 Releases


More Releases for Datamonitor

Datamonitor Healthcare Parkinson's Disease KOL Interviews
ReportsWorldwide has announced the addition of a new report title Datamonitor Healthcare Parkinson's Disease KOL Interviews to its growing collection of premium market research reports. March 16, 2017 Datamonitor Healthcare interviewed two neurologists, one based in Italy and the other in the US, to gauge their prescribing habits and views on current treatment options and challenges, late-stage clinical candidates and pricing and reimbursement considerations for Parkinson’s disease. The drugs discussed are listed
Datamonitor Healthcare Crohn's Disease KOL Interviews
ReportsWorldwide has announced the addition of a new report title Datamonitor Healthcare Crohn's Disease KOL Interviews to its growing collection of premium market research reports. April 05, 2017 Datamonitor Healthcare interviewed two inflammatory bowel disease experts, one based in France and the other in Italy, to gauge their views on marketed drugs for Crohn’s disease (CD), late-stage clinical candidates, treatment challenges and unmet needs and the future treatment of CD. The drugs
Datamonitor: MannKind - FDA's second rejection casts doubt on Afrezza's future
The FDA has requested further Phase III trials of MannKind's inhaled insulin Afrezza with its next generation Dreamboat inhaler before it can be approved. Should it eventually receive approval, Afrezza is likely to attract only a niche patient population, and Datamonitor forecasts that it will garner low sales compared to its competitors, due to safety fears and limited demand for inhaled insulin. MannKind has announced a further delay for its inhaled
Datamonitor: Australia - election outcome offers renewed hope for pharmaceutical …
Earlier in 2010, Medicines Australia negotiated a Memorandum of Understanding with the Labor government which was meant to provide stability for Australia's pharmaceutical industry. However, the election and subsequent hung parliament delayed its implementation. Now, with the Labor Party once more seated in power, Datamonitor expects the government to move forward with the existing agreement. More than two weeks after the Australian election resulted in a hung parliament, Julia Gillard's Labor
Datamonitor: Commercial Insight - Antihormonal Cancer Therapies on reports-resea …
Antihormonal cancer therapies are a class of drugs used predominantly in the treatment of breast cancer and prostate cancer. The high incidence of these tumor types translates into a significant commercial potential for drug developers. Collectively, the antihormonal therapy cancer brands generated sales of about $6.9 billion in the seven major pharmaceutical markets in 2008. Research and analysis highlights The antihormonals market was worth $6.9 billion in 2008 across the seven major
Datamonitor: Car Aftermarket in Europe 2009 – Overview on reports-research.com
The Light Vehicle Aftermarket is a huge, but highly competitive marketplace. The relative growth observed at European level masks a significant difference in progress between the most mature (Western European) markets and the nascent eastern European markets. The new Datamonitor report Car Aftermarket in Europe 2009 – Overview helps to understand the value of the European aftermarket, and how it is predicted to change in the next few years. It